Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GILEAD SCIENCES, INC.GILD · Entity 405 | Director | May 04, 2020 | May 05, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GILEAD SCIENCES, INC.
Report date May 04, 2020 · Filed May 05, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 54,860 |
Ending reported balance
After 2020-05-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-05-04 · Exercise / conversion · Acquired 2,416 · Balance 57,276 F1: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Row 2 · 2020-05-04 · Sale · Disposed 2,416 · Balance 54,860 |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.63 · Expires 2020-05-11 | Direct | 0 |
Reported balance
After 2020-05-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-05-04 · Exercise / conversion · Disposed 2,416 · Balance 0 F1: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2: The options vested quarterly over the first year of service and were fully vested on May 11, 2011. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
F2: The options vested quarterly over the first year of service and were fully vested on May 11, 2011.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 04, 2020 Filed May 5, 2020 20:28 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 2,416 | $0.00 Strike: $19.63 | $0.00 |
DisclosureSEC source: 0001127602-20-015427 · form4.xml · derivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,416 shares Expires 2020-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options vested quarterly over the first year of service and were fully vested on May 11, 2011. Read SEC document |
| May 04, 2020 Filed May 5, 2020 20:28 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,416 | $81.75 | $197,508.00 |
DisclosureSEC source: 0001127602-20-015427 · form4.xml · nonDerivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,860 Read SEC document |
| May 04, 2020 Filed May 5, 2020 20:28 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,416 | $19.63 | $47,426.08 |
DisclosureSEC source: 0001127602-20-015427 · form4.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,276 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 27, 2020 Filed Apr 29, 2020 23:28 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 2,413 | $0.00 Strike: $19.63 | $0.00 |
DisclosureSEC source: 0001127602-20-014714 · form4.xml · derivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,416 Underlying: Common Stock · 2,413 shares Expires 2020-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options vested quarterly over the first year of service and were fully vested on May 11, 2011. Read SEC document |
| April 27, 2020 Filed Apr 29, 2020 23:28 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,413 | $79.90 | $192,798.70 |
DisclosureSEC source: 0001127602-20-014714 · form4.xml · nonDerivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,860 Read SEC document |
| April 27, 2020 Filed Apr 29, 2020 23:28 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,413 | $19.63 | $47,367.19 |
DisclosureSEC source: 0001127602-20-014714 · form4.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,273 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 20, 2020 Filed Apr 21, 2020 23:42 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 2,413 | $0.00 Strike: $19.63 | $0.00 |
DisclosureSEC source: 0001127602-20-014247 · form4.xml · derivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,829 Underlying: Common Stock · 2,413 shares Expires 2020-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options vested quarterly over the first year of service and were fully vested on May 11, 2011. Read SEC document |
| April 20, 2020 Filed Apr 21, 2020 23:42 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,413 | $83.00 | $200,279.00 |
DisclosureSEC source: 0001127602-20-014247 · form4.xml · nonDerivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,860 Read SEC document |
| April 20, 2020 Filed Apr 21, 2020 23:42 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,413 | $19.63 | $47,367.19 |
DisclosureSEC source: 0001127602-20-014247 · form4.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,273 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 13, 2020 Filed Apr 14, 2020 19:52 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 2,413 | $0.00 Strike: $19.63 | $0.00 |
DisclosureSEC source: 0001127602-20-013679 · form4.xml · derivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,242 Underlying: Common Stock · 2,413 shares Expires 2020-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options vested quarterly over the first year of service and were fully vested on May 11, 2011. Read SEC document |
| April 13, 2020 Filed Apr 14, 2020 19:52 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,413 | $75.90 | $183,146.70 |
DisclosureSEC source: 0001127602-20-013679 · form4.xml · nonDerivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,860 Read SEC document |
| April 13, 2020 Filed Apr 14, 2020 19:52 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,413 | $19.63 | $47,367.19 |
DisclosureSEC source: 0001127602-20-013679 · form4.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,273 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 06, 2020 Filed Apr 7, 2020 21:34 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 2,413 | $0.00 Strike: $19.63 | $0.00 |
DisclosureSEC source: 0001127602-20-013405 · form4.xml · derivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,655 Underlying: Common Stock · 2,413 shares Expires 2020-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options vested quarterly over the first year of service and were fully vested on May 11, 2011. Read SEC document |
| April 06, 2020 Filed Apr 7, 2020 21:34 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,413 | $79.52 | $191,881.76 |
DisclosureSEC source: 0001127602-20-013405 · form4.xml · nonDerivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,860 Read SEC document |
| April 06, 2020 Filed Apr 7, 2020 21:34 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,413 | $19.63 | $47,367.19 |
DisclosureSEC source: 0001127602-20-013405 · form4.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,273 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 30, 2020 Filed Mar 31, 2020 19:00 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 2,413 | $0.00 Strike: $19.63 | $0.00 |
DisclosureSEC source: 0001127602-20-012212 · form4.xml · derivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,068 Underlying: Common Stock · 2,413 shares Expires 2020-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options vested quarterly over the first year of service and were fully vested on May 11, 2011. Read SEC document |
| March 30, 2020 Filed Mar 31, 2020 19:00 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,413 | $75.35 | $181,819.55 |
DisclosureSEC source: 0001127602-20-012212 · form4.xml · nonDerivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,860 Read SEC document |
| March 30, 2020 Filed Mar 31, 2020 19:00 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,413 | $19.63 | $47,367.19 |
DisclosureSEC source: 0001127602-20-012212 · form4.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,273 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 23, 2020 Filed Mar 25, 2020 00:42 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 2,413 | $0.00 Strike: $19.63 | $0.00 |
DisclosureSEC source: 0001127602-20-011900 · form4.xml · derivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,481 Underlying: Common Stock · 2,413 shares Expires 2020-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options vested quarterly over the first year of service and were fully vested on May 11, 2011. Read SEC document |
| March 23, 2020 Filed Mar 25, 2020 00:42 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,413 | $75.27 | $181,626.51 |
DisclosureSEC source: 0001127602-20-011900 · form4.xml · nonDerivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,860 Read SEC document |
| March 23, 2020 Filed Mar 25, 2020 00:42 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,413 | $19.63 | $47,367.19 |
DisclosureSEC source: 0001127602-20-011900 · form4.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,273 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 00:01 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 2,413 | $0.00 Strike: $19.63 | $0.00 |
DisclosureSEC source: 0001127602-20-011172 · form4.xml · derivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,894 Underlying: Common Stock · 2,413 shares Expires 2020-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options vested quarterly over the first year of service and were fully vested on May 11, 2011. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 00:01 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,413 | $67.26 | $162,298.38 |
DisclosureSEC source: 0001127602-20-011172 · form4.xml · nonDerivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,860 Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 00:01 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,413 | $19.63 | $47,367.19 |
DisclosureSEC source: 0001127602-20-011172 · form4.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,273 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 01:16 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 2,413 | $0.00 Strike: $19.63 | $0.00 |
DisclosureSEC source: 0001127602-20-010172 · form4.xml · derivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,307 Underlying: Common Stock · 2,413 shares Expires 2020-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: Options vest quarterly over the first year of service and will be fully vested on May 11, 2011. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 01:16 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,413 | $77.97 | $188,141.61 |
DisclosureSEC source: 0001127602-20-010172 · form4.xml · nonDerivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,860 Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 01:16 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,413 | $19.63 | $47,367.19 |
DisclosureSEC source: 0001127602-20-010172 · form4.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,273 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 08, 2019 Filed May 10, 2019 21:36 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 11,848 | $0.00 Strike: $66.07 | $0.00 |
DisclosureSEC source: 0001127602-19-018190 · form4.xml · derivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,848 Underlying: Common Stock · 11,848 shares Expires 2029-05-08 F3 · derivative.exercise_date: 25% of the shares subject to the option vest on each three-month anniversary from May 8, 2019 such that 100% of the shares subject to the option will be fully vested and exercisable upon the earlier of May 8, 2020 or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 08, 2019 Filed May 10, 2019 21:36 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 2,270 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-018190 · form4.xml · derivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,553 Underlying: Common Stock · 2,270 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units will vest upon the earlier of May 8, 2020, or the day immediately preceding the next regular annual stockholders meeting. F2 · derivative.expiration_date: 100% of the restricted stock units will vest upon the earlier of May 8, 2020, or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 01, 2019 Filed May 2, 2019 22:45 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 2,868 | $0.00 Strike: $22.02 | $0.00 |
DisclosureSEC source: 0001127602-19-017097 · form4.xml · derivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,868 shares Expires 2019-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The options vested quarterly over the first year of service and were fully vested on May 6, 2010. Read SEC document |
| May 01, 2019 Filed May 2, 2019 22:45 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,868 | $64.89 | $186,115.71 |
DisclosureSEC source: 0001127602-19-017097 · form4.xml · nonDerivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,860 F2 · price: Sale prices reported for the transactions reported here range from $64.58 to $65.37. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| May 01, 2019 Filed May 2, 2019 22:45 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,868 | $22.02 | $63,139.02 |
DisclosureSEC source: 0001127602-19-017097 · form4.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,728 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 24, 2019 Filed Apr 25, 2019 22:48 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 2,700 | $0.00 Strike: $22.02 | $0.00 |
DisclosureSEC source: 0001127602-19-016245 · form4.xml · derivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,868 Underlying: Common Stock · 2,700 shares Expires 2019-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options vested quarterly over the first year of service and were fully vested on May 6, 2010. Read SEC document |
| April 24, 2019 Filed Apr 25, 2019 22:48 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,700 | $62.61 | $169,054.02 |
DisclosureSEC source: 0001127602-19-016245 · form4.xml · nonDerivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,860 Read SEC document |
| April 24, 2019 Filed Apr 25, 2019 22:48 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,700 | $22.02 | $59,440.50 |
DisclosureSEC source: 0001127602-19-016245 · form4.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,560 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 17, 2019 Filed Apr 18, 2019 23:04 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 2,700 | $0.00 Strike: $22.02 | $0.00 |
DisclosureSEC source: 0001127602-19-015848 · form4.xml · derivative · entry 4 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,568 Underlying: Common Stock · 2,700 shares Expires 2019-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The options vested quarterly over the first year of service and were fully vested on May 6, 2010. Read SEC document |
| April 17, 2019 Filed Apr 18, 2019 23:04 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 100 | $64.66 | $6,466.00 |
DisclosureSEC source: 0001127602-19-015848 · form4.xml · nonDerivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,860 Read SEC document |
| April 17, 2019 Filed Apr 18, 2019 23:04 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,600 | $64.21 | $166,957.70 |
DisclosureSEC source: 0001127602-19-015848 · form4.xml · nonDerivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,960 F2 · price: Sale prices reported for the transactions reported here range from $63.65 to $64.63. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| April 17, 2019 Filed Apr 18, 2019 23:04 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,700 | $22.02 | $59,440.50 |
DisclosureSEC source: 0001127602-19-015848 · form4.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,560 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 10, 2019 Filed Apr 12, 2019 22:28 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 2,700 | $0.00 Strike: $22.02 | $0.00 |
DisclosureSEC source: 0001127602-19-015335 · form4.xml · derivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,268 Underlying: Common Stock · 2,700 shares Expires 2019-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options vested quarterly over the first year of service and were fully vested on May 6, 2010. Read SEC document |
| April 10, 2019 Filed Apr 12, 2019 22:28 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,700 | $67.23 | $181,521.00 |
DisclosureSEC source: 0001127602-19-015335 · form4.xml · nonDerivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,860 Read SEC document |
| April 10, 2019 Filed Apr 12, 2019 22:28 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,700 | $22.02 | $59,440.50 |
DisclosureSEC source: 0001127602-19-015335 · form4.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,560 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 03, 2019 Filed Apr 4, 2019 23:31 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 2,700 | $0.00 Strike: $22.02 | $0.00 |
DisclosureSEC source: 0001127602-19-014815 · form4.xml · derivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,968 Underlying: Common Stock · 2,700 shares Expires 2019-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options vested quarterly over the first year of service and were fully vested on May 6, 2010. Read SEC document |
| April 03, 2019 Filed Apr 4, 2019 23:31 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,700 | $66.74 | $180,198.00 |
DisclosureSEC source: 0001127602-19-014815 · form4.xml · nonDerivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,860 Read SEC document |
| April 03, 2019 Filed Apr 4, 2019 23:31 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,700 | $22.02 | $59,440.50 |
DisclosureSEC source: 0001127602-19-014815 · form4.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,560 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 27, 2019 Filed Mar 28, 2019 22:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 2,700 | $0.00 Strike: $22.02 | $0.00 |
DisclosureSEC source: 0001127602-19-013547 · form4.xml · derivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,668 Underlying: Common Stock · 2,700 shares Expires 2019-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options vested quarterly over the first year of service and were fully vested on May 6, 2010. Read SEC document |
| March 27, 2019 Filed Mar 28, 2019 22:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,700 | $64.14 | $173,178.00 |
DisclosureSEC source: 0001127602-19-013547 · form4.xml · nonDerivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,860 Read SEC document |
| March 27, 2019 Filed Mar 28, 2019 22:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,700 | $22.02 | $59,440.50 |
DisclosureSEC source: 0001127602-19-013547 · form4.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,560 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 20, 2019 Filed Mar 21, 2019 23:08 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 2,700 | $0.00 Strike: $22.02 | $0.00 |
DisclosureSEC source: 0001127602-19-012726 · form4.xml · derivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,368 Underlying: Common Stock · 2,700 shares Expires 2019-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options vested quarterly over the first year of service and were fully vested on May 6, 2010. Read SEC document |
| March 20, 2019 Filed Mar 21, 2019 23:08 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,700 | $65.07 | $175,689.00 |
DisclosureSEC source: 0001127602-19-012726 · form4.xml · nonDerivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,860 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.